nCounter® PanCancer IO 360™ Panel
みなさまの研究の一助に
nCounter PanCancer IO 360™ PanelとData Analysis Serviceは、腫瘍微小環境での免疫回避の影響についての研究や、免疫療法の潜在的な予後、予測、作用機序のシグネチャーの開発に取り組むがん免疫およびトランスレーショナルリサーチの研究者向けに特化してデザインされています。研究に役立つこのパネルは、潜在的に臨床可能な遺伝子とシグネチャーを提供します。これにより、腫瘍の免疫回避の知見を深めることができ、免疫標的治療などの治療に対する奏功の予測につながるかもしれません。このサービス一式には、必須遺伝子およびシグネチャーに関する知見を、腫瘍、微小環境、免疫応答の既知または潜在的な臨床的関連性と組み合わせたものが含まれています。
ナノストリングの360 Series Panel Collectionは、がん研究に対するシステムバイオロジーのアプローチに基づいており、腫瘍、微小環境、免疫応答の生物学に関与する高度にキュレーションされたコンテンツを1つの総括的アッセイにまとめることで、360度ビューの遺伝子発現情報を提供します。各パネルには、末梢性抑制の適応免疫応答の測定が可能で、チェックポイント阻害剤への応答に関連することが示されている、18遺伝子腫瘍炎症シグネチャー（TIS）が含まれています。
製品情報
Tumor-Microenvironment-Immune Response
NanoString synthesizes biological knowledge and large gene expression datasets together to train signatures of biological processes. For a given process, we use literature searches and expert knowledge to derive lists of candidate genes. For the PanCancer IO 360 panel, we evaluated the co-expression of candidate genes in data from The Cancer Genome Atlas (TCGA), discarding genes whose co-expression patterns are incompatible with measuring their putative biological process. This approach safeguards the interpretability of our signatures: we only report signatures whose genes show evidence for measuring the desired biology. Finally, we further exploit co-expression patterns to obtain optimal weights for each signature gene.
13 Biological Pathways and Processes
20 internal reference genes include overlapping genes from Hallmarks of Cancer PanCancer Collection for cross-panel comparisons.
The Tumor Inflammation Signature includes 18 functional genes known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade.
Includes 4 Areas of Immune Biology: IFN-ү-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes.
The tumor inflammation gene expression signature highlights the complex biology of the host immune microenvironment.
IO 360 Data Analysis Report
Data analysis report for the human* nCounter PanCancer IO360™ Gene Expression Panel
- Unique 360 view of gene expression for the tumor, microenvironment and immune response
- Interactive reports prepared by NanoString expert scientists
- 48 signatures including TIS, 14 signatures measuring immune cell populations and 34 novel signatures measuring important tumor and immune activities
- Tumor Inflammation Score (TIS) provided for each sample to determine “hot” and “cold” tumors
- Analysis includes sample signature score in relation to immune response
- All data undergoes QC and normalization
Report only available for analysis of human panel data – report not available for mouse
360 Series Product Comparison
Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.
関連リソース
アゼラスチンおよびフルチカゾンプロピオン酸エステルの併用または単剤療法に対する反応における鼻の免疫遺伝子発現
BACKGROUND: The combination of the antihistamine azelastine (AZE) with the corticosteroid fluticasone propionate (FP) in a single spray, has been reported to be significantly more effective at reducing allergic rhinitis (AR) symptoms than treatment with either corticosteroid or antihistamine monotherapy. However, the biological basis for enhanced symptom relief is not known.
骨髄の微小環境の遺伝子発現解析により、症候性疾患への進行に関連するくすぶり型多発性骨髄腫の特徴的な免疫型が判明
Background: We previously reported algorithms based on clinical parameters and plasma cell characteristics to identify patients with smoldering multiple myeloma (SMM) with higher risk of progressing who could benefit from early treatment. In this work, we analyzed differences in the immune bone marrow (BM) microenvironment in SMM to better understand the role of immune surveillance in disease progression and to identify immune biomarkers associated to higher risk of progression.
